Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Monopar Therapeutics Inc is a biotechnology business based in the US. Monopar Therapeutics shares (MNPR) are listed on the NASDAQ and all prices are listed in US Dollars. Monopar Therapeutics employs 6 staff and has a market cap (total outstanding shares value) of USD$84.2 million.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
52-week range | USD$4.28 - USD$10.55 |
---|---|
50-day moving average | USD$7.6152 |
200-day moving average | USD$5.9165 |
Wall St. target price | USD$35 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-0.4054 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Gross profit TTM | USD$0 |
---|---|
Return on assets TTM | -29.41% |
Return on equity TTM | -48.68% |
Profit margin | 0% |
Book value | $0.498 |
Market capitalisation | USD$84.2 million |
TTM: trailing 12 months
There are currently 23,595 Monopar Therapeutics shares held short by investors – that's known as Monopar Therapeutics's "short interest". This figure is 1.8% down from 24,031 last month.
There are a few different ways that this level of interest in shorting Monopar Therapeutics shares can be evaluated.
Monopar Therapeutics's "short interest ratio" (SIR) is the quantity of Monopar Therapeutics shares currently shorted divided by the average quantity of Monopar Therapeutics shares traded daily (recently around 138794.11764706). Monopar Therapeutics's SIR currently stands at 0.17. In other words for every 100,000 Monopar Therapeutics shares traded daily on the market, roughly 170 shares are currently held short.
However Monopar Therapeutics's short interest can also be evaluated against the total number of Monopar Therapeutics shares, or, against the total number of tradable Monopar Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Monopar Therapeutics's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Monopar Therapeutics shares in existence, roughly 0 shares are currently held short) or 0.0073% of the tradable shares (for every 100,000 tradable Monopar Therapeutics shares, roughly 7 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Monopar Therapeutics.
Find out more about how you can short Monopar Therapeutics stock.
We're not expecting Monopar Therapeutics to pay a dividend over the next 12 months.
Monopar Therapeutics Inc., a biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the United States. It is involved in developing Validive, a clonidine mucobuccal tablet that is in Phase III for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; Camsirubicin, a topoisomerase II-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart; and MNPR-101, a humanized monoclonal antibody for treating advanced solid cancers. The company has a collaboration Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; and NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19. Monopar Therapeutics Inc. was founded in 2014 and is headquartered in Wilmette, Illinois.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.